These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 32605859)
1. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859 [TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529 [TBL] [Abstract][Full Text] [Related]
3. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis. Gu L; Li X; Liu W Front Endocrinol (Lausanne); 2023; 14():1157857. PubMed ID: 37065739 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Chen H; Xiao L; Li J; Cui L; Huang W Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035 [TBL] [Abstract][Full Text] [Related]
5. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. Higano CS Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627 [TBL] [Abstract][Full Text] [Related]
6. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy. Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814 [TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis. Kunath F; Borgmann H; Blümle A; Keck B; Wullich B; Schmucker C; Sikic D; Roelle C; Schmidt S; Wahba A; Meerpohl JJ BMJ Open; 2015 Nov; 5(11):e008217. PubMed ID: 26567252 [TBL] [Abstract][Full Text] [Related]
8. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. George DJ; Dearnaley DP Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852 [TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?]. Merseburger AS; Sedding D; Hüter K Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324 [TBL] [Abstract][Full Text] [Related]
11. Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis. Ma C; Abeysekera IR; Xu W; Wang Y; Peng J; Li H Minerva Urol Nephrol; 2021 Jun; 73(3):276-282. PubMed ID: 33242948 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734 [TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy and side effects: are GnRH antagonists safer? Freedland SJ; Abrahamsson PA Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041 [TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists]. Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586 [TBL] [Abstract][Full Text] [Related]
16. Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies. Patel S; Zhu K; Dave CV; Ghajar M; Zhang Y; Saraiya B; Bandera EV; Khosrow-Khavar F Eur Urol Oncol; 2024 Sep; ():. PubMed ID: 39343637 [TBL] [Abstract][Full Text] [Related]
17. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Sciarra A; Fasulo A; Ciardi A; Petrangeli E; Gentilucci A; Maggi M; Innocenzi M; Pierella F; Gentile V; Salciccia S; Cattarino S Medicine (Baltimore); 2016 Jul; 95(27):e3845. PubMed ID: 27399062 [TBL] [Abstract][Full Text] [Related]
18. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403 [TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883 [TBL] [Abstract][Full Text] [Related]
20. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]